SCHEMBL6024367

SCHEMBL6024367

CNC(=O)c1ccc([N+](=O)[O-])c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
CTSK P43235 1/20 0.51
HCAR3 P49019 1/20 0.45
TSHR P16473 1/20 0.45
MAPT P10636 4/20 0.45
CASP6 P55212 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GPR55 Q9Y2T6 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30871059 1.00 ATM (0.51) ATMTDP1CTSKHCAR3TSHR
SCHEMBL2554714 0.87 AKR1C2 (0.54) HCAR3MAPTLMNAHTTALDH1A1
SCHEMBL4427078 0.85 HDAC6 (0.56) ATMTDP1CTSKCASP6HDAC1
SCHEMBL22734863 0.85 CASP6 (0.62) TDP1HCAR3TSHRMAPTCASP6
SCHEMBL6415835 0.84 MAPT (0.55) ATMTDP1CTSKTSHRMAPT
SCHEMBL24185865 0.83 HTT (0.56) ATMTDP1CTSKHCAR3HTT
SCHEMBL30663390 0.83 CTSK (0.48) ATMTDP1CTSKTSHRMAPT
SCHEMBL1418448 0.83 CTSK (0.54) ATMTDP1CTSKHCAR3MAPT
SCHEMBL385099 0.82 TSHR (0.68) TSHRMAPTLMNAHTTPOLB
SCHEMBL17486764 0.82 GPR35 (0.51) HCAR3TSHRMAPTCASP6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 EP disclosed
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
US-12091397-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. 2024-09-17 US disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
CN-111278816-B Dihydro quinolinones C4医药公司 2024-03-15 CN disclosed
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2023-06-22 US disclosed
CN-113004252-B Aryl imidazole derivative and application thereof 江苏先声药业有限公司 2023-06-09 CN disclosed
CN-113004252-A Aryl imidazole derivative and application thereof 江苏先声药业有限公司 2021-06-22 CN disclosed
US-7402696-B2 Benzene compounds AJINOMOTO CO., INC. (JP) 2008-07-22 US disclosed
US-20070105899-A1 Benzene compounds AJINOMOTO CO., INC. (JP) 2007-05-10 US disclosed
US-7138420-B2 Substituted benzimidazole compounds BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-11-21 US disclosed
US-20050203158-A1 Substituted benzimidazole compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-09-15 US disclosed
EP-1529046-A1 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-05-11 EP disclosed
WO-2004014905-A1 SUBSTITUTED BENZIMIDAZOLE COMPOUNDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091397-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 ATM 849/4885TDP1 2908/4885CTSK 2922/4885
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 ATM 849/4885TDP1 2908/4885CTSK 2922/4885
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 ATM 849/4885TDP1 2908/4885CTSK 2922/4885
US-20070105899-A1 Benzene compounds ACACB, ACACA, FABP4 ATM 293/4885TDP1 3735/4885CTSK 3476/4885
US-20050203158-A1 Substituted benzimidazole compounds ITK, BLK, SBK1 ATM 331/4885TDP1 2104/4885CTSK 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.